Get the Stockscreener App
531.08
0.37%
1.24
Madrigal Pharmaceuticals Inc stock is traded at $531.08, with a volume of 108.58K.
It is up +0.37% in the last 24 hours and up +22.08% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$529.84
Open:
$531.19
24h Volume:
108.58K
Relative Volume:
0.30
Market Cap:
$12.18B
Revenue:
$958.40M
Net Income/Loss:
$-288.28M
P/E Ratio:
-41.28
EPS:
-12.8641
Net Cash Flow:
$-193.02M
1W Performance:
+2.52%
1M Performance:
+22.08%
6M Performance:
+18.28%
1Y Performance:
+58.94%
1-Day Range:
$522.49
$539.98
1-Week Range:
$498.03
$545.25
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
531.09 | 12.15B | 958.40M | -288.28M | -193.02M | -12.86 |
VRTX
Vertex Pharmaceuticals Inc
|
440.26 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
758.57 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.78 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.08 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
311.46 | 34.24B | 5.36B | 287.73M | 924.18M | 2.5229 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts - marketbeat.com
What makes Madrigal Pharma (MDGL) one of the shorted biotech stocks to buy - MSN
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Madrigal Soars 5.87% on Strong Analyst Momentum and Institutional Shifts—Where to Now? - Bitget
Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
Understanding Momentum Shifts in (MDGL) - Stock Traders Daily
Madrigal grants equity awards to seven new employees - MSN
Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra - simplywall.st
Madrigal Pharmaceuticals grants equity awards to 20 new employees - MSN
Madrigal Pharmaceuticals (MDGL) surged on strong sales of its Rezdiffra drug - MSN
Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals stock dips after team presence at Liver Connect Conference sees doubled attendance - Traders Union
Madrigal Reports $212.8M in Q2 Rezdiffra Sales, Expands Global Pipeline and Secures $500M Financing - MSN
Loss Report: What are analysts price targets for Madrigal Pharmaceuticals Inc2026 Bull vs Bear & Technical Pattern Based Signals - baoquankhu1.vn
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug - Insider Monkey
Vanguard (MDGL) files amendment; reports 0 shares after Jan 12, 2026 realignment - Stock Titan
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains? - Yahoo Finance
Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? - Yahoo Finance
Madrigal Pharmaceuticals gains amid renewed takeover speculation - MSN
Rezdiffra Shows Promise as Madrigal’s Liver Drug Garners Positive Results - StocksToTrade
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 11.7% HigherShould You Buy? - marketbeat.com
Madrigal Surges 11.66%: A Volatile Breakout Defies Sector Stagnation as Bulls Test $572 - Bitget
Madrigal Grants Equity Awards to Seven New Employees - MyChesCo
Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Raised by Peak Financial Advisors LLC - marketbeat.com
Fundamentals Check: Is Madrigal Pharmaceuticals Inc benefiting from innovation trends2026 Momentum & Consistent Return Strategy Ideas - baoquankhu1.vn
JPMorgan Chase & Co. Sells 8,030 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - marketbeat.com
Aug Selloffs: How correlated is Madrigal Pharmaceuticals Inc to the S P5002026 Price Momentum & AI Powered Market Trend Analysis - baoquankhu1.vn
Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN
Madrigal slides more than 5% as wider Q4 loss tempers strong sales growth - MSN
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Madrigal grants inducement awards to five employees - MSN
Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Avoiding Lag: Real-Time Signals in (MDGL) Movement - Stock Traders Daily
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Groupama Asset Managment Sells 13,447 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
2,600 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Bamco Inc. NY - MarketBeat
Iron Triangle Partners LP Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
First Light Asset Management LLC Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Raised by Baker BROS. Advisors LP - MarketBeat
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.34%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):